These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 29906006)

  • 21. The efficacy and safety of topical 5% 5-fluorouracil in renal transplant recipients for the treatment of actinic keratoses.
    Ingham AI; Weightman W
    Australas J Dermatol; 2014 Aug; 55(3):204-8. PubMed ID: 24627952
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial.
    Pomerantz H; Hogan D; Eilers D; Swetter SM; Chen SC; Jacob SE; Warshaw EM; Stricklin G; Dellavalle RP; Sidhu-Malik N; Konnikov N; Werth VP; Keri J; Lew R; Weinstock MA;
    JAMA Dermatol; 2015 Sep; 151(9):952-60. PubMed ID: 25950503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DPD functional tests in plasma, fresh saliva and dried saliva samples as predictors of 5-fluorouracil exposure and occurrence of drug-related severe toxicity.
    Neto OV; Raymundo S; Franzoi MA; do Carmo Artmann A; Tegner M; Müller VV; Hahn RZ; Alves GV; Schwartsmann G; Linden R; Antunes MV
    Clin Biochem; 2018 Jun; 56():18-25. PubMed ID: 29625079
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metallic taste as a side effect of topical fluorouracil use.
    Han SY; Youker S
    J Drugs Dermatol; 2011 Oct; 10(10):1201-3. PubMed ID: 21968673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Topical fluorouracil for actinic keratoses and photoaging: a clinical and molecular analysis.
    Sachs DL; Kang S; Hammerberg C; Helfrich Y; Karimipour D; Orringer J; Johnson T; Hamilton TA; Fisher G; Voorhees JJ
    Arch Dermatol; 2009 Jun; 145(6):659-66. PubMed ID: 19528421
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation.
    Van Kuilenburg AB; Meinsma R; Zoetekouw L; Van Gennip AH
    Int J Cancer; 2002 Sep; 101(3):253-8. PubMed ID: 12209976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Five percent 5-fluorouracil in a cream or for superficial peels in the treatment of advanced photoaging of the forearms: a randomized comparative study.
    Guimarães CO; Miot HA; Bagatin E
    Dermatol Surg; 2014 Jun; 40(6):610-7. PubMed ID: 24852464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Severe systemic effects with topical fluorouracil.
    Prescrire Int; 2001 Dec; 10(56):184. PubMed ID: 11824445
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Symmetrical drug-related intertriginous and flexural exanthema secondary to topical 5-fluorouracil.
    Powers R; Gordon R; Roberts K; Kovach R
    Cutis; 2012 May; 89(5):225-8. PubMed ID: 22768435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: a randomized, vehicle-controlled clinical trial.
    Jorizzo J; Weiss J; Furst K; VandePol C; Levy SF
    Arch Dermatol; 2004 Jul; 140(7):813-6. PubMed ID: 15262691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel 0.5% fluorouracil cream is minimally absorbed into the systemic circulation yet is as effective as 5% fluorouracil cream.
    Levy S; Furst K; Chern W
    Cutis; 2002 Aug; 70(2 Suppl):14-21. PubMed ID: 12353676
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-dose 5-fluorouracil in combination with salicylic acid for the treatment of actinic keratoses on the hands and/or forearms - results of a non-interventional study.
    Reinhold U; Hadshiew I; Melzer A; Prechtl A
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):455-462. PubMed ID: 27549913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The management of actinic keratoses in the United States with topical fluorouracil: a pharmacoeconomic evaluation.
    Gupta AK
    Cutis; 2002 Aug; 70(2 Suppl):30-6. PubMed ID: 12353678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fluorouracil 5% and 0.5% creams for the treatment of actinic keratosis: equivalent efficacy with a lower concentration and more convenient dosing schedule.
    Jorizzo JL; Carney PS; Ko WT; Robins P; Weinkle SH; Werschler WP
    Cutis; 2004 Dec; 74(6 Suppl):18-23. PubMed ID: 15666898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of cryosurgery and 5-fluorouracil cream 0.5% combination therapy for the treatment of actinic keratosis.
    Hoover WD; Jorizzo JL; Clark AR; Feldman SR; Holbrook J; Huang KE
    Cutis; 2014 Nov; 94(5):255-9. PubMed ID: 25474455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Topical therapy for actinic keratoses, I: 5-Fluorouracil and imiquimod.
    Tutrone WD; Saini R; Caglar S; Weinberg JM; Crespo J
    Cutis; 2003 May; 71(5):365-70. PubMed ID: 12769403
    [TBL] [Abstract][Full Text] [Related]  

  • 37. One-week treatment with 0.5% fluorouracil cream prior to cryosurgery in patients with actinic keratoses: a double-blind, vehicle-controlled, long-term study.
    Jorizzo J; Weiss J; Vamvakias G
    J Drugs Dermatol; 2006 Feb; 5(2):133-9. PubMed ID: 16485881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-Dose 0.5% 5-Fluorouracil/10% Salicylic Acid Topical Solution in the Treatment of Actinic Keratoses.
    Herranz P; Morton C; Dirschka T; Azeredo RR; Roldán-Marín R
    J Cutan Med Surg; 2016 Nov; 20(6):555-561. PubMed ID: 27443886
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Case-based experience in the use of 5-fluorouracil cream 0.5% as monotherapy and in conjunction with glycolic acid peels for the treatment of actinic keratosis.
    Goldberg DJ
    J Cosmet Laser Ther; 2010 Feb; 12(1):42-6. PubMed ID: 20085453
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized, vehicle-controlled trials of topical 5-fluorouracil therapy for actinic keratosis treatment: an overview.
    Rahvar M; Lamel SA; Maibach HI
    Immunotherapy; 2012 Sep; 4(9):939-45. PubMed ID: 23046237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.